Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 1,718 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 1,718 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $6.85, for a total transaction of $11,768.30. Following the completion of the sale, the insider directly owned 2,846,592 shares of the company’s stock, valued at approximately $19,499,155.20. This trade represents a 0.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $7.26 on Tuesday. The company has a fifty day moving average of $6.84 and a two-hundred day moving average of $9.82. The company has a market capitalization of $281.83 million, a PE ratio of -1.82 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%.The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. On average, research analysts expect that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming increased its stake in Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after buying an additional 4,295 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after acquiring an additional 3,707 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in shares of Entrada Therapeutics in the second quarter valued at about $68,000. Jain Global LLC purchased a new stake in shares of Entrada Therapeutics in the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Entrada Therapeutics during the second quarter worth about $72,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains substantial at 86.39%, with Baker Bros. Advisors, Wellington Management, Millennium Management, Geode Capital and State Street among funds that recently increased their positions. Analysts’ consensus price target of $17.50 also remains well above the stock’s recent trading level, although the consensus rating is “Hold.”
• Neutral Sentiment: Entrada’s latest quarterly results beat expectations on adjusted earnings, reporting a loss of $0.95 per share versus the projected $1.06 loss. However, revenue of $0.88 million was well below the $2.92 million estimate, underscoring the company’s early-stage, clinical-biotechnology profile and ongoing losses.
• Negative Sentiment: Director Kush Parmar and major shareholder Ventures L.P. 5AM each disclosed the sale of 114,756 shares at an average price of $6.93, worth approximately $795,259. The disclosures appear to represent the same transaction reported through related filings, rather than two separate sales. The sale reduced the holder’s position by 3.87%, leaving approximately 2.85 million shares.
• Negative Sentiment: The same insiders also reported a separate sale of 1,718 shares at an average price of $6.85, valued at about $11,768. This reduced ownership by only 0.06%, making it a relatively minor transaction. Entrada Therapeutics Director Kush Parmar Sells Shares

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TRDA. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Guggenheim reduced their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Roth Capital set a $10.00 price target on shares of Entrada Therapeutics in a research note on Friday, May 8th. Finally, Oppenheimer raised their price objective on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.